Haleon's Results Show Headwinds in Over-the-Counter Business
Dow Jones10-29
0837 GMT - Haleon's update continues to show growth headwinds across the over-the-counter business, analysts at Bernstein say in a note. It should lead investors to question its midterm growth outlook, they add. The consumer-healthcare company cut its guidance to organic sales growth for the full year, now expecting it around 2.5% from previously 3% to 5%. Overall, the update is disappointing, the analysts say. Shares fall 13.5%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments